Overview

A Phase Study Assessing the Safety and Efficacy of PLB1004 in EGFR ex20ins Mutation Patients With Advanced and Metastatic Non-small Cell Lung Cancer(NSCLC)

Status:
RECRUITING
Trial end date:
2025-10-30
Target enrollment:
Participant gender:
Summary
It is a phase ,open-label, single-line, Multiple cohorts, Multicenter study assessing the Safety and Efficacy of PLB1004 in EGFR ex20ins mutation patients with Advanced and Metastatic Non-small Cell Lung Cancer(NSCLC).
Phase:
PHASE2
Details
Lead Sponsor:
Avistone Biotechnology Co., Ltd.